Tag Archives: Medical Equipment Market Report

Companies To Invest In Self-Diagnosis Devices

Use of medical devices for home based diagnosis and treatment of medical conditions is increasing. Technological developments in devices such as glucose monitors, insulin delivery devices, nebulizers and oxygen concentrators have enabled diagnosis and monitoring of many diseases at home. Remote control technology is also allowing healthcare professionals to support home based treatments which is leading to preference for home and self-care treatment.

 

THE BUSINESS RESEARCH COMPANY EXPECTS THE ****** MEDICAL EQUIPMENT MARKET SIZE TO GROW TO $448 BILLION BY 2021

 

Asia Pacific was the largest region in the medical equipment market in 2017, accounting for nearly one-third of the market share.

Companies To Invest In Self-Diagnosis Devices

Use of medical devices for the home based diagnosis and treatment of medical conditions is increasing. Technological developments in devices such as glucose monitors, insulin delivery devices, nebulizers and oxygen concentrators have enabled diagnosis and monitoring of many diseases at home. Remote control technology is also allowing healthcare professionals to support home based treatments which is leading to preference for home and self-care treatment.

THE BUSINESS RESEARCH COMPANY EXPECTS THE MEDICAL EQUIPMENT ****** MARKET TO GROW TO $448 BILLION BY 2021

Asia Pacific was the largest region in the medical equipment market in 2017, accounting for $123 billion or one-third of the market share.

Shared Medical Appointments: Balancing Efficiency With Patient Satisfaction

The shared medical appointments (SMA) model is a model generally defined as multiple patients being seen as a group by a multi-disciplinary medical care team for follow-up or routine care.  It is being adopted by hospitals to create awareness and counsel individual patients dealing with similar medical conditions. The SMA supplements the traditional physician-patient appointment. SMAs provide individual evaluation and disease management for each patient at the same time that they provide counseling to the patient within a group setting. SMAs are currently used to address diabetes, asthma, ulcerative colitis, MS, cancer, HIV, menopause, insomnia and stress.

The ****** Medical Equipment Market Is Valued At Nearly $375 Billion In 2017 According To TBRC’s Latest Report

Medical equipment devices are designed to aid diagnosis, monitoring or treatment of medical conditions.

Read More: https://www.thebusinessresearchcompany.com/report/medical-equipment-******-market-report-2018

The market is valued at nearly $375 billion in 2017 due to the economic growth, technological advancements and changes in lifestyle.

In the report, the ****** medical equipment market is divided into fifteen segments. In-vitro diagnostics was the largest segment in the medical equipment market with nearly 16% share and cardiovascular devices was the second largest segment in the medical equipment market with 15% share and the remaining 70% was occupied by the other thirteen segments namely, diagnostic equipment, orthopedic devices, hospital supplies, ophthalmic devices, nephrology and urology devices, patient monitoring devices, dental equipment and supplies, wound care devices, diabetes care devices, surgical equipment, ENT devices, anesthesia and respiratory devices and neurology devices.

Technological Advances Will Boost, Biosimilars Will Restrain The Market For Biologics

Investment in new generation biologics using technology such as physiology simulation modeling is helping the ****** market for biologics to grow at nearly 10% year on year, a report from The Business Research Company shows. Physiology simulation modeling gives test results within hours in the early stages of drug development. Biologics’ growth rate and the level of investment might be even higher if it were not that governments around the world are encouraging biosimilars in their efforts to reduce healthcare costs. Biosimilars are pharmaceuticals that are developed to have similar properties to a biologic that has already been approved. For example, In India, a new biosimilar policy called the ‘Guidelines on Similar Biologics’ prepared by the Central Drugs Standard Control Organization (CSDCO) is expected to give a major boost to the Indian biosimilars industry, so making it more competitive in the ****** market. In the EU, a pathway for approving biosimilar medicines has existed since 2003. These cheaper alternatives that compete with biologics discourage investment by limiting the time span over which the innovating companies can earn a return on their investment.